65,437 trials
Lung Cancer
Primary: Overall Survival — 14.4; 15.9; 16.4 months — p=0.12
HIV/AIDS · Insomnia
Primary: Insomnia Severity Index — -9.0; -3.4 score on a scale
Uveitis · Intermediate Uveitis · Posterior Uveitis
Primary: Change in Intraocular Pressure (IOP) — -0.1 mm Hg
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall · Stage II Bladder Cancer AJCC v8 · Stage II Renal Pelvis Cancer AJCC v8
Primary: Proportion of Participants With Complete Response (At 6 Months) — 0.5 proportion of participants
Peripheral Arterial Disease
Primary: Number of Participants With First Occurrence of Target Vessel Occlusion, Surgical Revascularization, Endovascular Revascularization, Major Amputation of Target Limb…
Epilepsies, Partial
Primary: Percentage of Participants With a Decrease (p<0.05) From Baseline in Threshold Value in Any 5 or More Points in Humphrey 24-2 Swedish Interactive Threshold Algorithm…
Osteoarthritis, Knee · Knee Arthritis
Primary: Baseline Assessment of Peak Knee Extensor Torque Preoperatively — 55.56; 58.33 Newton meters
Prostate Cancer
Primary: Number of Biopsy-proven Cancers (Gleason 6+) That Standard Imaging (mpMRI) Would Have Missed Compared With High Resolution Diffusion-weighted Imaging (DWI) PET-hrMRI on…
Hiv
Primary: The Level of Raltegravir Alone or Raltegravir /Lamivudine Required in the Plasma, Vagina and Rectum for 100% ex Vivo Protection From HIV — NA; 669.90; 265.10; 979.8 ng/mL
Asthma
Primary: Average Number of Days Without Asthma Symptoms (Symptom Free Days) During Post-intervention Follow-up Interviews (3, 5 and 7 Months) — 11.5; 11.4; 11.6 Days — p=<.05
Muscular Atrophy, Spinal
Primary: Part 1: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Risdiplam and Its Metabolite (M1) — 792; 987; 222; 263 h*ng/mL
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Phenylacetate, Benzoate, and Their Metabolites (Phenylacetylglutamine and Hippurate) — 300.7; 233.2; 69.77; 54.13…
Osteoarthritis, Knee
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 9; 4; 9; 8 Participants
Metabolic Syndrome
Primary: Feasibility of the Diet Intervention — 4782 prescribed diet visits
Nonhematologic Neoplasms, Advanced
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) Assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE) Version 4.03…